Phase III Trial of Induction Gemcitabine (G) or Paclitaxel (T) Plus Carboplatin (C) Followed by...
-
Upload
opal-parrish -
Category
Documents
-
view
216 -
download
0
Transcript of Phase III Trial of Induction Gemcitabine (G) or Paclitaxel (T) Plus Carboplatin (C) Followed by...
Phase III Trial of Induction Gemcitabine (G) or Paclitaxel (T) Plus Carboplatin (C) Followed by
Elective T Consolidation in Ovarian Cancer (OC), Stages IC to IV: Final Safety and Efficacy Report
M. Teneriello1, A. Gordon2, P. Lim3, M. Janicek4
1 US Oncology, Houston, TX and Texas Oncology, Austin, TX2 MD Anderson Cancer Center Orlando, Orlando, FL3 Center of Hope at Renown Regional Medical Center, Reno, NV4 OncoGyne, Scottsdale, AZ
Disclosure Information
The authors have no conflicts of interest to report.
This study was sponsored by Eli Lilly and Company.
Background
• Induction chemotherapy with a platinum agent and paclitaxel (T) is a standard of care for Stage IC-IV ovarian cancer (OC).
• Combination gemcitabine and carboplatin (GC) is approved for use in recurrent platinum-sensitive OC.
• Phase II trials have previously shown the combination of G plus cisplatin to be active as first-line therapy for OC.1-3
• Evidence suggests (SWOG 9701/GOG 178) that 12‑month T consolidation (Tcon) improves progression-free survival (PFS).4
• The current study was designed to compare GC to standard first-line therapy, followed by Tcon.
1 Belpomme D, et al. Gynecol Oncol 2003.2 Nogué M, et al. Anticancer Drugs 2002.3 Bauknecht T, et al. Int J Gynecol Cancer 2003.4 Markman M, et al. J Clin Oncol 2003.
Background
• The study was initiated in October 2002 as a multi- center, open-label, dual-arm, randomized, Phase III, superiority trial.
• In June 2004, Tcon was changed from mandatory to elective after 362 patients had been enrolled.
• Planned enrollment was 1208 patients. In August 2006, the protocol was modified to allow PFS as primary endpoint. Subsequently, enrollment was stopped at 919 patients, an adequate sample size for estimation of PFS.
• The trial was stopped in October 2009 after an ad hoc futility analysis showed low probability of a positive PFS result.
Objectives
Primary Objective
• To compare PFS in the experimental arm (GC) to the control arm, paclitaxel and carboplatin (TC)
Secondary Objectives
• To compare efficacy of the two regimens with respect to response rate and OS
• To compare adverse events related to each regimen
Study Design
Induction GCGemcitabine 1000 mg/m2 D1,8
Carboplatin AUC 5 D1x 6 cycles q21 days
RANDOMIZE
Induction TCPaclitaxel 175 mg/m2 D1Carboplatin AUC 6 D1
x 6 cycles q21 days
Anything other than CR(PR, SD, PD)
Anything other than CR(PR, SD, PD)
Clinical CR
Single-agent crossover (CO-T)Paclitaxel 175 mg/m2
D1, q21 days
Single-agent crossover (CO-G)Gemcitabine 1000 mg/m2
D1, D8; q21 days
Elective Tcon therapyPaclitaxel 135 mg/m2 q28 days
for 12 cycles
Abbreviations: AUC, area under curve; CO-T, crossover to paclitaxel; CO-G, crossover to gemcitabine; CR, complete response; D, day; PD, progressive disease; PR, partial response; q, every; SD, stable disease; Tcon, paclitaxel consolidation.
Methods
• IRB approval was required at all sites.
• Surgery had to be ≤12 weeks prior to enrollment and performance status (PS) was 0, 1, or 2.
• A pathologic diagnosis of primary peritoneal, epithelial ovarian, or fallopian tube carcinoma was required, Stage IC, II, III, or IV.
• No prior gemcitabine (G), prior radiation, or prior chemotherapy for any abdominal or pelvic tumor.
Abbreviations: IRB, Institutional Review Board.
• Best tumor response was assessed in patients with measurable disease using RECIST criteria.
• CA-125 assessments in patients with non-measurable disease followed GCIG criteria.
• Adverse events were assessed using the NCI Common Toxicity Criteria (v 2.0).
• The 2-sided Fisher’s exact test was used to determine P-values for response and toxicity.
• Survival was assessed using Kaplan-Meier method and log rank test for P-values.
Methods…continued
Abbreviations: GCIG, Gynecologic Cancer Intergroup; NCI, National Cancer Institute; RECIST, ResponseEvaluation Criteria in Solid Tumors.
Patient Disposition
Abbreviations: N, number of patients enrolled; n, number of patients in group; NA, not available.
Patients randomly assigned(n = 916)
Allocated to GC (n = 417)Received GC (n = 411)Withdrew (n = 6)
Discontinued (n = 165) Patient request (n = 58) Toxicity (n = 26) Physician request (n = 20) Death (n = 6) >5 week therapy delay (n = 5) Progressive disease (n = 5) Other (n = 33) Unknown (n = 12)
Allocated to TC (n = 414)Received TC (n = 409)Withdrew (n = 5)
Enrolled(N = 919)
Discontinued (n = 148) Patient request (n = 39) Toxicity (n = 37) Physician request (n = 11) Death (n = 8) >5 week therapy delay (n = 7) Progressive disease (n = 6) Other (n = 19) Unknown (n = 6)
Excluded (n = 3)Not meeting inclusion criteria (NA)Other (NA)
Received Tcon (n = 169) Received Tcon (n = 183)
Received CO-G (n = 78)
Excluded (clerical errors) (n = 85)
Received CO-T (n = 77)
Patient Characteristics
ParameterGC
N=417 TC
N=414P-value
Age
Median age, years (range) 60 (22-84) 61 (22-86) 0.439
Age ≤65 years, n (%) 282 (67.6) 274 (66.2)0.695
Age >65 years, n (%) 135 (32.4) 139 (33.6)
Race, n (%)
Caucasian 379 (90.9) 379 (91.5)
0.961
Black 12 (2.9) 13 (3.1)
Asian 5 (1.2) 5 (1.2)
Native American 2 (0.5) 1 (0.2)
Other 19 (4.6) 16 (3.9)
Zubrod performance status, n (%)
0 239 (57.3) 232 (56.0)
1 139 (33.3) 157 (37.9) 0.887
2 27 (6.5) 16 (3.9)
Patient Characteristics…continued
ParameterGC
N=417 TC
N=414P-value
Origin of disease, n (%)
Ovary 355 (85.1) 362 (87.4)0.524
Peritoneum 56 (13.4) 50 (12.1)
Extent of residual disease, n (%)
Measurable 139 (33.3) 114 (27.5)0.063
Non-measurable 276 (66.2) 300 (72.5)
FIGO stage at initial surgery, n (%)
IC 21 (5.0) 22 (5.3)
0.929 II 44 (10.6) 39 (9.4)
III 284 (68.1) 289 (69.8)
IV 68 (16.3) 63 (15.2)
Tumor size after debulking, n (%)
<2 cm 309 (74.1) 314 (75.8)0.638
≥2 cm 102 (24.5) 96 (23.2)
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics.
Patient Characteristics…continued
ParameterGC
N=417 TC
N=414P-value
Histology, n (%)
Mucinous 10 (2.4) 10 (2.4)
Serous 283 (63.2) 276 (66.7)
Endometroid 44 (10.6) 40 (9.7)
Undifferentiated 7 (1.7) 7 (1.7)
Clear cell 21 (5.0) 23 (5.6) 0.960
Mixed epithelial 9 (2.2) 13 (3.1)
Transitional cell 3 (0.7) 1 (0.2)
Adenocarcinoma 22 (5.3) 23 (5.6)
Other 17 (4.1) 21 (5.1)
CA-125
Patients evaluated, n 416 4140.869
Baseline, mean U/ml ± SD 492.8 ± 1138.6 479.8 ± 1117.0
Abbreviation: SD, standard deviation.
Adverse Events – Induction
Adverse event, n (%)GC
N=412TC
N=408P-value
Grade 3-4 anemia 113 (27.4) 31 (7.6) 0.00010.0001
Grade 3/4 thrombocytopenia165 (40.0)114 (27.7)
39 (9.6)9 (2.2)
0.00010.0001**
Platelet transfusion 11 (2.7) 0 (0.0) 0.00090.0009
Grade 2 neuropathy 9 (2.2) 57 (14.0) <0.0001<0.0001
Grade 2-3 alopecia 30 (7.3) 208 (51.0) <0.0001<0.0001
Grade 3-4 neutropenia 332 (80.6) 321 (78.7) 0.544
Grade 3-4 febrile neutropenia 7 (1.7) 12 (2.9) 0.256
Grade 3-4 fatigue 23 (5.6) 15 (3.7) 0.245
Grade 3-4 nausea 21 (5.1) 18 (4.4) 0.743
Grade 3-4 vomiting 16 (3.9) 17 (4.2) 0.861
Grade 3-4 myalgia 1 (0.2) 3 (0.7) 0.372
Red blood cell transfusion 15 (3.6) 9 (2.2) 0.300
* P-value compares combined Grade 3-4 thrombocytopenia between groups.
Adverse Events – Consolidation
Adverse event, n (%)Tcon-GN=169
Tcon-TN=183
P-value
Grade 2 neuropathy 25 (14.8) 50 (27.3) 0.0040.004
Grade 3-4 neutropenia 29 (17.2) 30 (16.4) 0.887
Grade 3-4 febrile neutropenia 0 (0.0) 0 (0.0) -
Grade 3/4 thrombocytopenia3 (1.8)1 (0.6)
0 (0.0)0 (0.0)
0.052*
Grade 3-4 anemia 2 (1.2) 0 (0.0) 0.230
Grade 3-4 fatigue 3 (1.8) 2 (1.1) 0.674
Grade 3-4 nausea 1 (0.6) 0 (0.0) 0.480
Grade 3-4 vomiting 2 (1.2) 0 (0.0) 0.230
Grade 3-4 myalgia 1 (0.6) 0 (0.0) 0.480
Grade 2-3 alopecia 76 (45.0) 67 (36.6) 0.128
Red blood cell transfusion 1 (0.6) 0 (0.0) 0.480
Platelet transfusion 1 (0.6) 0 (0.0) 0.480
* P-value compares combined Grade 3-4 thrombocytopenia between groups.
Abbreviations: Tcon-G, paclitaxel consolidation after GC;Tcon-T, paclitaxel consolidation after TC.
Response: Induction (Measurable Disease)
Best response, n (%)GC
N=139TC
N=114P-value
ORR (CR+PR) 94 (67.6) 81 (71.1) 0.771
DCR (CR+PR+SD) 116 (83.5) 97 (85.1) 0.999
Complete response (CR)* 57 (41.0) 50 (43.9) 0.795
Partial response (PR) 37 (26.6) 31 (27.2) -
Stable disease (SD) 22 (15.8) 16 (14.0) -
Progressive disease (PD) 14 (10.1) 11 (9.6) -
Data not available 9 (6.5) 6 (5.3) -
Abbreviations: ORR, Overall Response Rate; DCR,Disease Control Rate.
* CR required a normalized CA-125.
Response: Crossover (Measurable Disease)
Best response, n (%)CO-GN=28
CO-TN=33
P-value
ORR (CR+PR) 10 (35.7) 10 (30.3) 0.784
DCR (CR+PR+SD) 14 (50.0) 15 (45.5) 0.796
Complete response (CR)* 5 (17.9) 1 (3.0) 0.084
Partial response (PR) 5 (17.9) 9 (27.3) -
Stable disease (SD) 4 (14.3) 5 (15.2) -
Progressive disease (PD) 13 (46.4) 16 (48.5) -
Data not available 1 (3.5) 2 (6.0) -
* CR required a normalized CA-125.
Progression-Free Survival (ITT)
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Survival Time (months)
Su
rviv
al P
rob
abil
ity
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
PFS GC (N=417) TC (N=414) P-value
Patients censored, n (%) 122 (29.3) 134 (32.4)
Median, months (95% CI)
20.0 (17.9, 22.2) 22.2 (19.0, 25.7) 0.199
Abbreviations: CI, confidence interval; ITT, intent-to-treat.
Progression-Free Survival: Further Analyses
CR after induction + Tcon (N=342) – Tcon (N=175) P-value
Median, months (95% CI) 30.0 (25.7, 33.9) 23.7 (19.8, 36.7) 0.295
CR - with consolidation GC (N=163) TC (N=179)
Median, months (95% CI) 27.2 (23.9, 36.1) 30.6 (26.0, 36.5) 0.803
CR - no consolidation GC (N=97) TC (N=78)
Median, months (95% CI) 23.4 (17.8, 36.7) 27.4 (15.8, 43.8) 0.793
Crossover CO-G (N=78) CO-T (N=77)
Median, months (95% CI) 9.3 (7.7, 11.8) 10.2 (7.2, 12.5) 0.918
Overall Survival
Intent-to-treat GC (N=417) TC (N=414) P-value
Patients censored, n (%) 220 (52.8) 254 (61.4)
Median, months (95% CI) 43.8 (38.8, 48.4) 57.3 (48.5, 64.0) 0.0130.013
Adjusted by covariates* GC (N=400) TC (N=395)
Hazard ratio (95% CI) 1.22 (0.99, 1.52) 0.067
CR after induction + Tcon (N=342) – Tcon (N=175)
Patients censored, n (%) 228 (66.7) 118 (67.4)
Median, months (95% CI) 65.6 (54.7, - ) 51.4 (48.4, - ) 0.0410.041
* Cox regression analysis was performed using baseline patient characteristics: performance status, tumor size after debulking, FIGO stage, and histology.
Summary
• In 2006 the protocol was modified to allow PFS as primary endpoint and enrollment was stopped at 919 patients.
• Demographics were well balanced between arms.
• Toxicity profiles were consistent with prior clinical experience.
• Response results were not statistically different comparing the two induction or crossover arms.
Summary
• For PFS, the primary endpoint, there was no difference for induction, consolidation, and crossover groups.
• Adjusting for significant covariates, there was no significant difference in OS between the two arms.
• Subset analysis suggested that OS may be improved for patients receiving Tcon after achieving CR.
• The OS analysis was severely limited by: early study closure, the high rate of censored data, unrecoverable data, and non-randomization for the consolidation treatment.
Conclusions
• GC did not offer an advantage over standard of care TC for first-line chemotherapy in OC.
• Paclitaxel consolidation may have improved OS, but analysis was limited by study design and high censorship.
• The utility of paclitaxel consolidation cannot be answered by this trial.
We thank...
• The 85 trial Investigators at 63 sites in the United States.
• The Lilly Medical team.
• Our patients.
Acknowledgements
Phase III Trial of Induction Gemcitabine (G) or Paclitaxel (T) Plus Carboplatin (C) Followed by
Elective T Consolidation in Ovarian Cancer (OC), Stages IC to IV: Final Safety and Efficacy Report
M. Teneriello1, A. Gordon2, P. Lim3, M. Janicek4
1 US Oncology, Houston, TX and Texas Oncology, Austin, TX2 MD Anderson Cancer Center Orlando, Orlando, FL3 Center of Hope at Renown Regional Medical Center, Reno, NV4 OncoGyne, Scottsdale, AZ
Discussion Slides
Drug Administration
ParameterGC
N=412TC
N=408
Tcon-G
N=169
Tcon-TN=183
CO-GN=78
CO-TN=77
Total cycles administered, n 2221 2194 1583 1760 417 513
Mean cycles administered, n 5.4 5.4 9.4 9.6 5.3 6.7
Median cycles administered, n 6 6 12 12 5 6
Cycles with dose reduction, n/(%)312
(14.0)107(4.9)
23(1.4)
40(2.3)
32(7.7)
25(4.9)
Abbreviations: Tcon-G, paclitaxel consolidation after GC; Tcon-T, paclitaxel consolidation after TC.
Adverse Events – Crossover
Adverse event, n (%)CO-GN=78
CO-TN=77
P-value
Grade 3-4 neutropenia 52 (66.7) 30 (39.0) 0.00070.0007
Grade 3/4 thrombocytopenia12 (15.4)
5 (6.4)3 (3.9)1 (1.3) 0.0040.004**
Grade 2 neuropathy 7 (9.0) 22 (28.6) 0.00190.0019
Grade 3-4 febrile neutropenia 2 (2.6) 2 (2.6) >0.999
Grade 3-4 anemia 2 (2.6) 2 (2.6) >0.999
Grade 3-4 fatigue 5 (6.4) 3 (3.9) 0.719
Grade 3-4 nausea 0 (0.0) 1 (1.3) 0.497
Grade 3-4 vomiting 1 (1.3) 1 (1.3) >0.999
Grade 3-4 myalgia 1 (1.3) 3 (3.9) 0.367
Grade 2-3 alopecia 30 (38.5) 38 (49.4) 0.077
Red blood cell transfusion 2 (2.6) 0 (0.0) 0.497
Platelet transfusion 0 (0.0) 0 (0.0) -
* P-value compares combined Grade 3-4 thrombocytopenia between groups.
Overall Survival: Further Analyses
CR after induction + Tcon (N=342) – Tcon (N=175) P-value
Patients censored, n (%) 228 (66.7) 118 (67.4)
Median, months (95% CI) 65.6 (54.7, - ) 51.4 (48.4, - ) 0.0410.041
CR - with consolidation GC (N=163) TC (N=179)
Patients censored, n (%) 98 (60.1) 130 (72.6)
Median, months (95% CI) 56.1 (47.3, - ) - ( - , - ) 0.0350.035
CR - no consolidation GC (N=97) TC (N=78)
Patients censored, n (%) 63 (64.9) 55 (70.5)
Median, months (95% CI) - ( - , - ) 64.0 (48.4, - ) 0.1910.191
Crossover CO-G (N=78) CO-T (N=77)
Patients censored, n (%) 30 (38.5) 23 (29.9)
Median, months (95% CI) 26.4 (21.3, 37.1) 25.7 (20.6, 34.2) 0.7350.735
29
Patient Accrual S302
0
200
400
600
800
1000
1200
Planned Accrual
Cum
ulati
ve P
atien
ts, n
10/2002 8/2006
Actual Accrual
9/2005
30
7 2455
95158
231
311
404472
511545 561 570 571
0
100
200
300
400
500
600
700
800
Jun-03
Dec-03
Jun-04
Dec-04
Jun-05
Dec-05
Jun-06
Dec-06
Jun-07
Dec-07
Jun-08
Dec-08
Jun-09
Dec-09
Cum
ulati
ve E
vent
s636 Planned PFS Events
Cumulative PFS Events S302